N/A
Completed N=100
Comparison of Tranexamic to Epsilon Aminocaproic Acid: a Prospective Analysis of Blood Conservation in Cardiac Surgery
Source: ClinicalTrials.gov NCT01248104 ↗Enrolled (actual)
100
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcomePrimary: Total Transfusion Amounts — 161; 116 mililiters — p=0.35
Summary
We designed a prospective double-blinded randomized trial in an attempt to detect a difference between tranexamic acid (TXA) and epsilon aminocaproic acid (EACA) in reducing transfusion in patients undergoing cardiac surgery.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Total Transfusion Amounts |
161; 116 | 0.35 |
Eligibility Criteria
Inclusion Criteria
- Is the subject 18 years of age or older?
- Is the subject scheduled for primary cardiac surgery utilizing cardiopulmonary bypass(CPB)?
- Is the subject more than 30 kg ( 66 lbs)?
- Does subject understand English?
Exclusion Criteria
- Does the subject have existing coagulation defects (INR > 1.5, platelets 3x normal) ?
- Is the subject having emergency cardiac surgery, complex aortic surgery, combination valve/CABG surgeries, or redo cardiac surgery?
- Is the subject having any procedure where CPB is not anticipated?
- Is the patient weight greater than 150 kg?
Data sourced from ClinicalTrials.gov (NCT01248104). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.